Roles of Testosterone Replacement in Cardiac Ischemia-Reperfusion Injury

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 21, Issue 1, 2016, Pages 27-43

  Pongkan, Wanpitak ^a,b   Chattipakorn, Siriporn C ^a,b   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

aging; heart; ischemia reperfusion injury; testosterone

Indexed keywords

LACTATE DEHYDROGENASE; TESTOSTERONE;

CELL VIABILITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME RELEASE; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANIMAL; CARDIAC MUSCLE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; HEART; MALE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PROTECTION; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; HEART; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROGNOSIS; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE;

EID: 84951320786     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415587977     Document Type: Review

References (129)

1. Handelsman DJ, Zajac JD,. Androgen deficiency and replacement therapy in men. Med J Aust. 2004; 180 (10): 529-535.
2. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89 (12): 5920-5926.
3. Spratt DI, Cox P, Orav J, Moloney J, Bigos T,. Reproductive axis suppression in acute illness is related to disease severity. J Clin Endocrinol Metab. 1993; 76 (6): 1548-1554.
4. Kalyani RR, Gavini S, Dobs AS,. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007; 36 (2): 333-48.
5. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA,. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013; 2 (6): e000272.
6. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007; 92 (11): 4241-7.
7. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C,. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60 (7): 762-769.
8. Kaufman JM, Vermeulen A,. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005; 26 (6): 833-876.
9. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001; 86 (2): 724-731.
10. Roubinian JR, Papoian R, Talal N,. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest. 1977; 59 (6): 1066-1070.
11. Haffner SM, Karhapaa P, Mykkanen L, Laakso M,. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994; 43 (2): 212-219.
12. Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008; 93 (5): 1834-1840.
13. Ferdinandy P, Schulz R, Baxter GF,. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007; 59 (4): 418-458.
14. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P,. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999; 99 (9): 1165-1172.
15. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Gender differences on the risk evaluation of acute coronary syndromes: the CARDIO2000 study. Prev Cardiol. 2003; 6 (2): 71-77.
16. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015; 131 (4): e29-e322.
17. Li L, Guo CY, Jia EZ, et al. Testosterone is negatively associated with the severity of coronary atherosclerosis in men. Asian J Androl. 2012; 14 (6): 875-878.
18. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS,. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000; 21 (11): 890-894.
19. Wu FC, von Eckardstein A,. Androgens and coronary artery disease. Endocr Rev. 2003; 24 (2): 183-217.
20. Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2009; 142 (1): 50-55.
21. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006; 114 (17): 1829-1837.
22. Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007; 19 (2): 176-182.
23. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010; 31 (12): 1494-1501.
24. Borst SE, Quindry JC, Yarrow JF, et al. Testosterone administration induces protection against global myocardial ischemia. Horm Metab Res. 2010; 42 (2): 122-129.
25. Chen Y, Fu L, Han Y, et al. Testosterone replacement therapy promotes angiogenesis after acute myocardial infarction by enhancing expression of cytokines HIF-1a, SDF-1a and VEGF. Eur J Pharmacol. 2012; 684 (1-3): 116-124.
26. Herring MJ, Oskui PM, Hale SL, Kloner RA,. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc. 2013; 2 (4): e000271.
27. Brouillette J, Rivard K, Lizotte E, Fiset C,. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res. 2005; 65 (1): 148-157.
28. Tsang S, Wu S, Liu J, Wong TM,. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol. 2008; 153 (4): 693-709.
29. O'Connor EK, Ivey JR, Bowles DK,. Differential effects of androgens on coronary blood flow regulation and arteriolar diameter in intact and castrated swine. Biol Sex Differ. 2012; 3 (1): 10.
30. Alexandersen P, Haarbo J, Byrjalsen I, et al. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res. 1999; 84 (7): 813-819.
31. Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009; 6 (12): 3274-3288.
32. Wang M, Wang Y, Abarbanell A, et al. Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. Surgery. 2009; 146 (2): 138-144.
33. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014; 9 (1): e85805.
34. Cavasin MA, Tao ZY, Yu AL, Yang XP,. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol. 2006; 290 (5): H2043-H2050.
35. Ceballos G, Figueroa L, Rubio I, et al. Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol. 1999; 33 (5): 691-697.
36. Crisostomo PR, Wang M, Wairiuko GM, Morrell ED, Meldrum DR,. Brief exposure to exogenous testosterone increases death signaling and adversely affects myocardial function after ischemia. Am J Physiol Regul Integr Comp Physiol. 2006; 290 (5): R1168-R1174.
37. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ,. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998; 98 (3): 256-261.
38. Winters SJ,. Androgen: endocrine physiology and pharmacology. In: Lin GC, Erinoff L, eds. Anabolic Steroid Abuse. Rockville, MD: National Institute on Drug Abuse; 1990: 113-130.
39. Ling S, Komesaroff PA, Sudhir K,. Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women. Endocr Metab Immune Disord Drug Targets. 2009; 9 (1): 29-37.
40. Papamitsou T, Barlagiannis D, Papaliagkas V, Kotanidou E, Dermentzopoulou-Theodoridou M,. Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells-an ultrastructural and immunohistochemical study. Med Sci Monit. 2011; 17 (9): BR266-BR273.
41. Schaible TF, Malhotra A, Ciambrone G, Scheuer J,. The effects of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circ Res. 1984; 54 (1): 38-49.
42. Scheuer J, Malhotra A, Schaible TF, Capasso J,. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res. 1987; 61 (1): 12-19.
43. Golden KL, Marsh JD, Jiang Y, Moulden J,. Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol. 2005; 152 (3): 479-483.
44. Heinlein CA, Chang C,. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol. 2002; 16 (10): 2181-2187.
45. Perusquia M, Stallone JN,. Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites. Am J Physiol Heart Circ Physiol. 2010; 298 (5): H1301-H1307.
46. Witayavanitkul N, Woranush W, Bupha-Intr T, Wattanapermpool J,. Testosterone regulates cardiac contractile activation by modulating SERCA but not NCX activity. Am J Physiol Heart Circ Physiol. 2013; 304 (3): H465-H472.
47. Curl CL, Delbridge LM, Canny BJ, Wendt IR,. Testosterone modulates cardiomyocyte Ca(2+) handling and contractile function. Physiol Res. 2009; 58 (2): 293-297.
48. Trifunovic B, Norton GR, Duffield MJ, Avraam P, Woodiwiss AJ,. An androgenic steroid decreases left ventricular compliance in rats. Am J Physiol. 1995; 268 (3 pt 2): H1096-H1105.
49. Mayuga KA, Parker M, Sukthanker ND, et al. Effects of age and gender on the QT response to exercise. Am J Cardiol. 2001; 87 (2): 163-167.
50. Schwartz JB, Volterrani M, Caminiti G, et al. Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure. Int J Androl. 2011; 34 (5 pt 2): e415-e421.
51. Charbit B, Christin-Maitre S, Demolis JL, Soustre E, Young J, Funck-Brentano C,. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol. 2009; 103 (6): 887-890.
52. Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA,. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. Pharmacol Ther. 2010; 127 (1): 9-18.
53. Sedlak T, Shufelt C, Iribarren C, Merz CN,. Sex hormones and the QT interval: a review. J Womens Health (Larchmt). 2012; 21 (9): 933-941.
54. Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS,. Effect of testosterone therapy on QT dispersion in men with heart failure. Am J Cardiol. 2003; 92 (10): 1241-3.
55. van Noord C, Dorr M, Sturkenboom MC, et al. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol. 2010; 25 (1): 21-28.
56. Ezaki K, Nakagawa M, Taniguchi Y, et al. Gender differences in the ST segment: effect of androgen-deprivation therapy and possible role of testosterone. Circ J. 2010; 74 (11): 2448-2454.
57. Jaffe MD,. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977; 39 (11): 1217-1222.
58. Tenover JS,. Androgen administration to aging men. Endocrinol Metab Clin North Am. 1994; 23 (4): 877-892.
59. Jeppesen LL, Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS, Winther K,. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol. 1996; 16 (6): 749-754.
60. Tsuneda T, Yamashita T, Kato T, et al. Deficiency of testosterone associates with the substrate of atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2009; 20 (9): 1055-1060.
61. Tsang S, Wong SS, Wu S, Kravtsov GM, Wong TM,. Testosterone-augmented contractile responses to α1-and β1-adrenoceptor stimulation are associated with increased activities of RyR, SERCA, and NCX in the heart. Am J Physiol Cell Physiol. 2009; 296 (4): C766-C782.
62. Er F, Gassanov N, Brandt MC, Madershahian N, Hoppe UC,. Impact of dihydrotestosterone on L-type calcium channels in human ventricular cardiomyocytes. Endocr Res. 2009; 34 (3): 59-67.
63. Perrier E, Kerfant BG, Lalevee N, et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation. 2004; 110 (7): 776-783.
64. Golden KL, Marsh JD, Jiang Y, Brown T, Moulden J,. Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes. Am J Physiol Endocrinol Metab. 2003; 285 (3): E449-E453.
65. Golden KL, Marsh JD, Jiang Y,. Castration reduces mRNA levels for calcium regulatory proteins in rat heart. Endocrine. 2002; 19 (3): 339-344.
66. Chrysohoou C, Panagiotakos D, Pitsavos C, et al. Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria study. Rev Diabet Stud. 2013; 10 (1): 27-38.
67. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013; 310 (17): 1829-1836.
68. Kelly DM, Jones TH,. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013; 217 (3): R47-R71.
69. Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011; 34 (7): 1669-1675.
70. Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009; 20 (3): 613-620.
71. Hu X, Rui L, Zhu T, et al. Low testosterone level in middle-aged male patients with coronary artery disease. Eur J Intern Med. 2011; 22 (6): e133-e136.
72. Agarwal M, Naghi J, Philip K, et al. Growth hormone and testosterone in heart failure therapy. Expert Opin Pharmacother. 2010; 11 (11): 1835-1844.
73. Sarkar NN,. Hormonal profiles behind the heart of a man. Cardiol J. 2009; 16 (4): 300-306.
74. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003; 87 (2-3): 179-183.
75. Guder G, Allolio B, Angermann CE, Stork S,. Androgen deficiency in heart failure. Curr Heart Fail Rep. 2011; 8 (2): 131-139.
76. Liu PY, Death AK, Handelsman DJ,. Androgens and cardiovascular disease. Endocr Rev. 2003; 24 (3): 313-340.
77. Yeap BB,. Androgens and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2010; 17 (3): 269-276.
78. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010; 363 (2): 109-122.
79. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM,. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015; 90 (2): 224-251.
80. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000; 102 (16): 1906-1911.
81. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004; 90 (8): 871-876.
82. Liu J, Tsang S, Wong TM,. Testosterone is required for delayed cardioprotection and enhanced heat shock protein 70 expression induced by preconditioning. Endocrinology. 2006; 147 (10): 4569-4577.
83. Rubio-Gayosso I, Ramirez-Sanchez I, Ita-Islas I, et al. Testosterone metabolites mediate its effects on myocardial damage induced by ischemia/reperfusion in male Wistar rats. Steroids. 2013; 78 (3): 362-369.
84. Nahrendorf M, Frantz S, Hu K, et al. Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res. 2003; 57 (2): 370-378.
85. Herring M, Hale SL, Shi J, et al. Supraphysiological testosterone levels shorten the QT interval but do not alter total anatomic myocardial infarct size in rabbits with acute myocardial infarction. Cardiol Pharmacol. 2014; 3 (1): 1000115.
86. Callies F, Stromer H, Schwinger RH, et al. Administration of testosterone is associated with a reduced susceptibility to myocardial ischemia. Endocrinology. 2003; 144 (10): 4478-4483.
87. Nam UH, Wang M, Crisostomo PR, et al. The effect of chronic exogenous androgen on myocardial function following acute ischemia-reperfusion in hosts with different baseline levels of sex steroids. J Surg Res. 2007; 142 (1): 113-118.
88. Wang M, Tsai BM, Kher A, et al. Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2005; 288 (1): H221-H226.
89. Bennett NC, Gardiner RA, Hooper JD, et al. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 2010; 42 (6): 813-827.
90. Klocker H, Gromoll J, Cato ACB., The androgen receptor: molecular biology. In: Nieshchlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. 3rd ed. United Kingdom: Cambridge University Press; 2004: 39-92.
91. Michels G, Hoppe UC,. Rapid actions of androgens. Front Neuroendocrinol. 2008; 29 (2): 182-198.
92. Vicencio JM, Ibarra C, Estrada M, et al. Testosterone induces an intracellular calcium increase by a nongenomic mechanism in cultured rat cardiac myocytes. Endocrinology. 2006; 147 (3): 1386-1395.
93. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24 (27): 4448-4456.
94. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010; 102 (1): 39-46.
95. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006; 24 (24): 3979-3983.
96. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91 (4): 1305-1308.
97. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87 (2): 599-603.
98. Smith MR,. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004; 63 (4): 742-745.
99. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW,. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008; 113 (12): 3290-3297.
100. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV,. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302 (8): 866-873.
101. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360 (24): 2516-2527.
102. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009; 27 (21): 3452-3458.
103. Huang C, Gu H, Zhang W, Herrmann JL, Wang M,. Testosterone-down-regulated Akt pathway during cardiac ischemia/reperfusion: a mechanism involving BAD, Bcl-2 and FOXO3a. J Surg Res. 2010; 164 (1): e1-e11.
104. Wranicz JK, Rosiak M, Cygankiewicz I, Kula P, Kula K, Zareba W,. Sex steroids and heart rate variability in patients after myocardial infarction. Ann Noninvasive Electrocardiol. 2004; 9 (2): 156-161.
105. Ruige JB, Ouwens DM, Kaufman JM,. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013; 98 (11): 4300-4310.
106. Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab. 2012; 97 (1): 179-189.
107. Gu HF, Yang YM, Xu ZR., Relationship between androgen levels and pathological changes of coronary atherosclerosis in elderly males [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007; 36 (4): 382-385.
108. Turhan S, Tulunay C, Gulec S, et al. The association between androgen levels and premature coronary artery disease in men. Coronary Artery Dis. 2007; 18 (3): 159-162.
109. Helaly MA, Daoud E, El-Mashad N,. Does the serum testosterone level have a relation to coronary artery disease in elderly men? Curr Gerontol Geriatr Res. 2011; 2011: 791765.
110. Zhang XJ, Li XY, Cao TT, Ye L,. Correlation of endogenous androgen and androgen receptor level with coronary artery diseases in elderly males [in Chinese]. Zhonghua yi xue za zhi. 2011; 91 (14): 984-986.
111. Svartberg J, von Muhlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E,. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006; 259 (6): 576-582.
112. Niccoli G, Milardi D, D'Amario D, et al. Hypotestosteronemia is frequent in ST-elevation myocardial infarction patients and is associated with coronary microvascular obstruction [published online May 12, 2014]. Eur J Prev Cardiol. 2014.
113. Zhao SP, Li XP,. The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol. 1998; 63 (2): 161-164.
114. Sieminska L, Wojciechowska C, Swietochowska E, et al. Serum free testosterone in men with coronary artery atherosclerosis. Med Sci Monit. 2003; 9 (5): CR162-CR166.
115. Dunajska K, Milewicz A, Szymczak J, et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004; 7 (3): 197-204.
116. Cao J, Zou H, Zhu BP, et al. Sex hormones and androgen receptor: risk factors of coronary heart disease in elderly men. Chin Med Sci J. 2010; 25 (1): 44-49.
117. Adamkiewicz M, Zgliczyńki S, Stowiliska-Srzednicka J, et al. The relationship between plasma androgens (dehydroepiandrosterone sulfate and testosterone) and coronary arteriosclerosis in men: the lower the androgens, the higher the coronary score of arteriosclerosis. Aging Male. 1999; 2 (1): 22-32.
118. Alkamel A, Shafiee A, Jalali A, Boroumand M, Nozari Y,. The association between premature coronary artery disease and level of testosterone in young adult males. Arch Iran Med. 2014; 17 (8): 545-550.
119. Wranicz JK, Cygankiewicz I, Kula P, et al. Endogenous estradiol and testosterone may predispose toward atherogenic lipid profile, but higher blood level of testosterone is associated with lower number of stenoses in the coronary arteries of men with coronary disease. Int J Biomed Sci. 2006; 2 (2): 135-142.
120. Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013; 75 (3): 282-288.
121. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999; 99 (13): 1666-1670.
122. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K,. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009; 161 (3): 443-449.
123. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P,. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999; 100 (16): 1690-1696.
124. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014; 48 (9): 1138-1144.
125. Stergiopoulos K, Brennan JJ, Mathews R, Setaro JF, Kort S,. Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. Vasc Health Risk Manag. 2008; 4 (6): 1475-1480.
126. Smith AM, English KM, Malkin CJ, Jones RD, Jones TH, Channer KS,. Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol. 2005; 152 (2): 285-291.
127. Mirdamadi A, Garakyaraghi M, Pourmoghaddas A, Bahmani A, Mahmoudi H, Gharipour M,. Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure. Biomed Res Int. 2014; 2014: 392432.
128. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009; 54 (10): 919-927.
129. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS,. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006; 27 (1): 57-64.